Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13572995 | 0.89 | ALDH1A1 (0.38) | L3MBTL1PER2GRM5POLB | |
| SCHEMBL22017935 | 0.84 | GAA (0.39) | L3MBTL1PER2POLBCRY2 | |
| SCHEMBL22017468 | 0.83 | PER2 (0.38) | PER2CRY2 | |
| SCHEMBL22017742 | 0.83 | CYP2D6 (0.36) | L3MBTL1PER2POLBCRY2 | |
| SCHEMBL22017743 | 0.83 | PER2 (0.32) | PER2 | |
| SCHEMBL19364816 | 0.82 | PER2 (0.42) | L3MBTL1PER2CRY2 | |
| SCHEMBL22017462 | 0.80 | PER2 (0.33) | PER2CRY2 | |
| SCHEMBL22017740 | 0.80 | HRH3 (0.40) | GRM5 | |
| SCHEMBL22017741 | 0.78 | PIK3CD (0.46) | L3MBTL1PER2POLBCRY2 | |
| SCHEMBL22017463 | 0.78 | ALDH1A1 (0.37) | L3MBTL1PER2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | L3MBTL1 455/4885PER2 3231/4885GRM5 4626/4885 |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | L3MBTL1 455/4885PER2 3231/4885GRM5 4626/4885 |
| US-11332485-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | L3MBTL1 455/4885PER2 3231/4885GRM5 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.